Neoadjuvant chemotherapy for metastatic colon cancer: A cautionary note

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9073-9078

  Bilchik, Anton J ^a   Poston, Graeme ^b   Curley, Steven A ^c   Strasberg, Steven ^d   Saltz, Leonard ^e   Adam, Rene ^f   Nordlinger, Bernard ^f   Rougier, Philippe ^f   Rosen, Lee S ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d USA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG TOLERABILITY; FATTY LIVER; HUMAN; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; SINUSOIDAL OBSTRUCTION SYNDROME; VEIN OCCLUSION; ADJUVANT THERAPY; ARTICLE; COLON TUMOR; CONTROLLED CLINICAL TRIAL; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; PRACTICE GUIDELINES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33644822617     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.2334     Document Type: Review

References (30)

1. Fernandez FG, Drebin JA, Linehan DC, et al: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240:438-447, 2004
2. Choti MA, Sitzmann JV, Tiburi MF, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759-766, 2002
3. Pawlik TM, Scoggins CR, Zorzi D, et al: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722, 2005
4. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
5. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
6. Wolmark N, Wieand HS, Kuebler JP, et al: A phase III trial comparing FU/LV to FU/LV + oxaliplatin in stage II and III carcinoma of the colon: Results of NSABP Protocol C-07. J Clin Oncol 23:246S, 2005 (suppl 16, abstr 3500)
7. de Gramont A, Boni C, Navarro M, et al: Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. J Clin Oncol 23:2465, 2005 (suppl 16, abstr 3501)
8. Hickish T, Boni C, Navarro M, et al: FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. J Clin Oncol 22:275, 2004 (suppl, abstr 3619)
9. Bismuth H, Adam R: Reduction of non-resectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 25:40-46, 1998 (suppl 5)
10. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases down-staged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644-657, 2004
11. Delaunoit T, Alberts SR, Sargent DJ, et al: Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 16:425-429, 2005
12. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
13. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005
14. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23:S1S, 2005 (suppl 16, abstr 2)
15. Roman CD, Choy H, Nanney L, et al: Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 105:43-47, 2002
16. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005
17. Rubbia-Brandt L, Audard V, Sartoretti P, et al: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncoi 15:460-466, 2004
18. Fernandez FG, Ritter J, Linehan DC, et al: Effect of steatohepatitis associated with irinotecan or oxaliplatin pre-treatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845-853, 2005
19. DeLeve LD, Shulman HM, McDonald GB: Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22:27-42, 2002
20. Tisman G, MacDonald D, Shindeli N, et al: Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 22:3202-3204, 2004
21. Adam R, Sebagh M, Plasse M, et al: Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM). J Clin Oncol 23:2535, 2005 (suppl 16, abstr 3529)
22. Parikh AA, Gentner B, Wu TT, et al: Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 7:1082-1088, 2003
23. Kooby DA, Fong Y, Suriawinata A, et al: Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7:1034-1044, 2003
24. Behrns KE, Tsiotos GG, DeSouza NF, et al: Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 2:292-298, 1998
25. Peppercorn PD, Reznek RH, Wilson P, et al: Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 77:2008-2011, 1998
26. Jacobs JE, Birnbaum BA, Shapiro MA, et al: Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. Am J Roentgenol 171:659-664, 1998
27. Murata Y, Ogawa Y, Saibara T, et al: Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7:1299-1304, 2000
28. Nemoto Y, Saibara T, Ogawa Y, et al: Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Intern Med 41:345-350, 2002
29. Nordlinger B, Sorbye H, Debois M, et al: Feasibility and risks of pre-operative chemotherapy (CT) with FolFox 4 and surgery for resectable colorectal cancer liver metastases (LM): Interim results of the EORTC Intergroup randomized phase III study 40983. J Clin Oncol 23:253S, 2005 (suppl 16, abstr 3528)
30. Poston GJ: The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol 31:325-330, 2005